Ascaris Lumbricoides β Carbonic Anhydrase: a Potential Target Enzyme for Treatment of Ascariasis
Overview
Tropical Medicine
Authors
Affiliations
Background: A parasitic roundworm, Ascaris lumbricoides, is the causative agent of ascariasis, with approximately 760 million cases around the world. Helminthic infections occur with a high prevalence mostly in tropical and developing xcountries. Therefore, design of affordable broad-spectrum anti-helminthic agents against a variety of pathogens, including not only A. lumbricoides but also hookworms and whipworms, is desirable. Beta carbonic anhydrases (β-CAs) are considered promising targets of novel anthelminthics because these enzymes are present in various parasites, while completely absent in vertebrates.
Methods: In this study, we identified an A. lumbricoides β-CA (AIBCA) protein from protein sequence data using bioinformatics tools. We used computational biology resources and methods (including InterPro, CATH/Gene3D, KEGG, and METACYC) to analyze AlBCA and define potential roles of this enzyme in biological pathways. The AlBCA gene was cloned into pFastBac1, and recombinant AIBCA was produced in sf-9 insect cells. Kinetics of AlBCA were analyzed by a stopped-flow method.
Results: Multiple sequence alignment revealed that AIBCA contains the two sequence motifs, CXDXR and HXXC, typical for β-CAs. Recombinant AIBCA showed significant CA catalytic activity with kcat of 6.0 × 10(5) s(-1) and kcat/KM of 4.3 × 10(7) M(-1) s(-1). The classical CA inhibitor, acetazolamide, showed an inhibition constant of 84.1 nM. Computational modeling suggests that the molecular architecture of AIBCA is highly similar to several other known β-CA structures. Functional predictions suggest that AIBCA might play a role in bicarbonate-mediated metabolic pathways, such as gluconeogenesis and removal of metabolically produced cyanate.
Conclusions: These results open new avenues to further investigate the precise functions of β-CAs in parasites and suggest that novel β-CA specific inhibitors should be developed and tested against helminthic diseases.
Gheibzadeh M, Manyumwa C, Tastan Bishop O, Shahbani Zahiri H, Parkkila S, Zolfaghari Emameh R Biology (Basel). 2023; 12(6).
PMID: 37372055 PMC: 10295459. DOI: 10.3390/biology12060770.
Haapanen S, Angeli A, Tolvanen M, Zolfaghari Emameh R, Supuran C, Parkkila S J Enzyme Inhib Med Chem. 2023; 38(1):2184299.
PMID: 36856011 PMC: 9980027. DOI: 10.1080/14756366.2023.2184299.
Aspatwar A, Bonardi A, Aisala H, Zueva K, Primmer C, Lumme J J Enzyme Inhib Med Chem. 2023; 38(1):2167988.
PMID: 36647786 PMC: 9848252. DOI: 10.1080/14756366.2023.2167988.
Zolfaghari Emameh R, Barker H, Turpeinen H, Parkkila S, Hytonen V Malar J. 2022; 21(1):189.
PMID: 35706028 PMC: 9199335. DOI: 10.1186/s12936-022-04186-7.
The Targeting of Noncoding RNAs by Quercetin in Cancer Prevention and Therapy.
Wang M, Chen X, Yu F, Zhang L, Zhang Y, Chang W Oxid Med Cell Longev. 2022; 2022:4330681.
PMID: 35656022 PMC: 9155922. DOI: 10.1155/2022/4330681.